Cargando…
Uveitis: Molecular Pathogenesis and Emerging Therapies
The profound impact that vision loss has on human activities and quality of life necessitates understanding the etiology of potentially blinding diseases and their clinical management. The unique anatomic features of the eye and its sequestration from peripheral immune system also provides a framewo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119754/ https://www.ncbi.nlm.nih.gov/pubmed/33995347 http://dx.doi.org/10.3389/fimmu.2021.623725 |
_version_ | 1783691920696934400 |
---|---|
author | Egwuagu, Charles E. Alhakeem, Sahar A. Mbanefo, Evaristus C. |
author_facet | Egwuagu, Charles E. Alhakeem, Sahar A. Mbanefo, Evaristus C. |
author_sort | Egwuagu, Charles E. |
collection | PubMed |
description | The profound impact that vision loss has on human activities and quality of life necessitates understanding the etiology of potentially blinding diseases and their clinical management. The unique anatomic features of the eye and its sequestration from peripheral immune system also provides a framework for studying other diseases in immune privileged sites and validating basic immunological principles. Thus, early studies of intraocular inflammatory diseases (uveitis) were at the forefront of research on organ transplantation. These studies laid the groundwork for foundational discoveries on how immune system distinguishes self from non-self and established current concepts of acquired immune tolerance and autoimmunity. Our charge in this review is to examine how advances in molecular cell biology and immunology over the past 3 decades have contributed to the understanding of mechanisms that underlie immunopathogenesis of uveitis. Particular emphasis is on how advances in biotechnology have been leveraged in developing biologics and cell-based immunotherapies for uveitis and other neuroinflammatory diseases. |
format | Online Article Text |
id | pubmed-8119754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81197542021-05-15 Uveitis: Molecular Pathogenesis and Emerging Therapies Egwuagu, Charles E. Alhakeem, Sahar A. Mbanefo, Evaristus C. Front Immunol Immunology The profound impact that vision loss has on human activities and quality of life necessitates understanding the etiology of potentially blinding diseases and their clinical management. The unique anatomic features of the eye and its sequestration from peripheral immune system also provides a framework for studying other diseases in immune privileged sites and validating basic immunological principles. Thus, early studies of intraocular inflammatory diseases (uveitis) were at the forefront of research on organ transplantation. These studies laid the groundwork for foundational discoveries on how immune system distinguishes self from non-self and established current concepts of acquired immune tolerance and autoimmunity. Our charge in this review is to examine how advances in molecular cell biology and immunology over the past 3 decades have contributed to the understanding of mechanisms that underlie immunopathogenesis of uveitis. Particular emphasis is on how advances in biotechnology have been leveraged in developing biologics and cell-based immunotherapies for uveitis and other neuroinflammatory diseases. Frontiers Media S.A. 2021-04-30 /pmc/articles/PMC8119754/ /pubmed/33995347 http://dx.doi.org/10.3389/fimmu.2021.623725 Text en Copyright © 2021 Egwuagu, Alhakeem and Mbanefo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Egwuagu, Charles E. Alhakeem, Sahar A. Mbanefo, Evaristus C. Uveitis: Molecular Pathogenesis and Emerging Therapies |
title | Uveitis: Molecular Pathogenesis and Emerging Therapies |
title_full | Uveitis: Molecular Pathogenesis and Emerging Therapies |
title_fullStr | Uveitis: Molecular Pathogenesis and Emerging Therapies |
title_full_unstemmed | Uveitis: Molecular Pathogenesis and Emerging Therapies |
title_short | Uveitis: Molecular Pathogenesis and Emerging Therapies |
title_sort | uveitis: molecular pathogenesis and emerging therapies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119754/ https://www.ncbi.nlm.nih.gov/pubmed/33995347 http://dx.doi.org/10.3389/fimmu.2021.623725 |
work_keys_str_mv | AT egwuagucharlese uveitismolecularpathogenesisandemergingtherapies AT alhakeemsahara uveitismolecularpathogenesisandemergingtherapies AT mbanefoevaristusc uveitismolecularpathogenesisandemergingtherapies |